Research · PMID 42600634
Reviewed by Neal Rouzier, MD, Preventive Medicine · Sep 2026
Effects of Glucagon-Like Peptide-1 Receptor Agonists as Weight Loss Drugs on Pancreatitis and Pancreatic Cancer: A Meta-Analysis.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · August 2026 · Xinai Zhong, Yueqi Zhao, Mengyao Han, Qianqian Zheng, Qianqian Cheng, et al.
What this study found
This meta-analysis aimed to clarify the association between glucagon-like peptide-1 receptor agonists, used for weight management in obesity, and the risks of pancreatitis and pancreatic cancer. We systematically searched PubMed, Web of Science, Embase, the Cochrane Library, and Scopus through June 15, 2026, for clinical studies conducted in obese populations.
How RAGMD uses this study
Clinical questions this paper informs
Synthesis lives on the evidence question — this page shows where the study sits in that analysis.
Primary study
Do GLP-1 agonists increase pancreatitis risk?
Early signals raised pancreatitis concern, but large trials and post-marketing data have not confirmed a strong causal increase at population level. Caution remains reasonable in patients with prior pancreatitis.
Open evidence analysisSupporting literature
Does GLP-1 treatment cause meaningful muscle loss?
GLP-1 therapies reduce weight through fat and lean mass loss; lean loss is partly proportional to total weight lost. Resistance training and adequate protein may mitigate but not eliminate lean mass decline.
Open evidence analysisSupporting literature
Do GLP-1 receptor agonists reduce major cardiovascular events?
GLP-1 receptor agonists with cardiovascular outcome trials (including liraglutide and semaglutide in selected populations) reduce major adverse cardiovascular events beyond glucose lowering in high-risk patients with type 2 diabetes or obesity.
Open evidence analysisSupporting literature
Do patients regain weight after stopping GLP-1 therapy?
Clinical trials and observational follow-up show substantial weight regain after GLP-1 discontinuation, suggesting chronic therapy may be needed to maintain benefit unless durable lifestyle changes are established.
Open evidence analysisSupporting literature
Do GLP-1 drugs increase thyroid cancer risk in humans?
Rodent C-cell tumor signals led to contraindications in medullary thyroid carcinoma and MEN2. Human epidemiologic data have not established a clear excess of thyroid cancer, but long-term surveillance continues.
Open evidence analysisSupporting literature
How does tirzepatide compare with semaglutide for weight loss?
Head-to-head trials suggest tirzepatide produces greater average weight loss than semaglutide at studied doses, with broadly similar gastrointestinal side-effect profiles. Long-term cardiovascular outcome comparisons are ongoing.
Open evidence analysisSupporting literature
Can resistance training and protein intake preserve muscle during GLP-1 weight loss?
Exercise and higher protein intake are biologically plausible strategies to attenuate lean mass loss during significant GLP-1-mediated weight reduction, though dedicated outcome trials are still emerging.
Open evidence analysis